Literature DB >> 1899454

From the Food and Drug Administration.

S L Nightingale1.   

Abstract

Mesh:

Substances:

Year:  1991        PMID: 1899454

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  9 in total

1.  Hypertensive Crises.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  1999-06

2.  Management of patients with Björk-Shiley prosthetic valves.

Authors:  T Treasure
Journal:  Br Heart J       Date:  1991-11

3.  Prolonged high-dose administration of sodium nitroprusside in the intensive care unit.

Authors:  C Mandragos; C Sarantopoulos; A Amygdalou; P K Behrakis
Journal:  Intensive Care Med       Date:  1998-08       Impact factor: 17.440

Review 4.  Comparative tolerability profile of hypertensive crisis treatments.

Authors:  E Grossman; A N Ironi; F H Messerli
Journal:  Drug Saf       Date:  1998-08       Impact factor: 5.606

Review 5.  Adverse effects of direct-acting vasodilators.

Authors:  P Armario; R Hernandez del Rey; H Pardell
Journal:  Drug Saf       Date:  1994-08       Impact factor: 5.606

6.  The NO donor sodium nitroprusside: evaluation of skeletal muscle vascular and metabolic dysfunction.

Authors:  Daniel M Hirai; Steven W Copp; Scott K Ferguson; Clark T Holdsworth; Timothy I Musch; David C Poole
Journal:  Microvasc Res       Date:  2012-11-19       Impact factor: 3.514

Review 7.  Emergency room management of hypertensive urgencies and emergencies.

Authors:  D G Vidt
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 May-Jun       Impact factor: 3.738

Review 8.  Sodium nitroprusside in 2014: A clinical concepts review.

Authors:  Daniel G Hottinger; David S Beebe; Thomas Kozhimannil; Richard C Prielipp; Kumar G Belani
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2014-10

Review 9.  Management of hypertensive crises in the elderly.

Authors:  Abbas Alshami; Carlos Romero; America Avila; Joseph Varon
Journal:  J Geriatr Cardiol       Date:  2018-07       Impact factor: 3.327

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.